Trial Profile
Sorafenib in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 26 Apr 2019
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver disorders; Lung disorders
- Focus Therapeutic Use
- Acronyms SHPS
- 28 Feb 2019 Primary endpoint (Difference in changes in alveolar-arterial oxygen gradient between sorafenib and placebo groups) has not been met published in the Liver transplantation
- 28 Feb 2019 Results assessing effect of sorafenib in patients with hepatopulmonary syndrome on the alveolar-arterial oxygen gradient published in the Liver Transplantation
- 14 Mar 2018 Status changed from recruiting to discontinued.